Author:
Da Binlin,Wu Wei,Guo Wuhua,Xiong Kai,Chen Chao,Ke Qiao,Zhang Moran,Li Taishun,Xiao Jiangqiang,Wang Lei,Zhang Ming,Zhang Feng,Zhuge Yuzheng
Abstract
AbstractThis study aimed to perform the first external validation of the modified Child-Turcotte-Pugh score based on plasma ammonia (aCTP) and compare it with other risk scoring systems to predict survival in patients with cirrhosis after transjugular intrahepatic portosystemic shunt (TIPS) placement. We retrospectively reviewed 473 patients from three cohorts between January 2016 and June 2022 and compared the aCTP score with the Child-Turcotte-Pugh (CTP) score, albumin-bilirubin (ALBI), model for end-stage liver disease (MELD) and sodium MELD (MELD-Na) in predicting transplant-free survival by the concordance index (C-index), area under the receiver operating characteristic curve, calibration plot, and decision curve analysis (DCA) curve. The median follow-up time was 29 months, during which a total of 62 (20.74%) patients died or underwent liver transplantation. The survival curves for the three aCTP grades differed significantly. Patients with aCTP grade C had a shorter expected lifespan than patients with aCTP grades A and B (P < 0.0001). The aCTP score showed the best discriminative performance using the C-index compared with other scores at each time point during follow-up, it also showed better calibration in the calibration plot and the lowest Brier scores, and it also showed a higher net benefit than the other scores in the DCA curve. The aCTP score outperformed the other risk scores in predicting survival after TIPS placement in patients with cirrhosis and may be useful for risk stratification and survival prediction.
Funder
National Natural Science Foundation of China
Nanjing Health Science, Technology Development Special Fund project - Outstanding Youth Fund project
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Gines, P. et al. Liver cirrhosis. Lancet 398(10308), 1359–1376 (2021).
2. Tripathi, D. et al. Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension. Gut 69(7), 1173–1192 (2020).
3. Garcia-Tsao, G., Abraldes, J. G., Berzigotti, A. & Bosch, J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 65(1), 310–335 (2017).
4. Xiong, B. et al. The added value of sarcopenia on existing risk scores to predict mortality after TIPS placement: A multicenter study. Acad. Radiol. S1076-6332(23)00123-X (2023).
5. Pugh, R. N., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C. & Williams, R. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 60(8), 646–649 (1973).